BXU-001 is under clinical development by Baylx and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BXU-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BXU-001 overview

BXU-001 is under development for the treatment of idiopathic pulmonary fibrosis (IPF), severe COVID-19 pneumonia with mild to moderate acute respiratory distress syndrome, rheumatoid arthritis, inflammatory bowel disease (IBD) and for multiple sclerosis.  The drug candidate consists of allogeneic human umbilical cord tissue-derived mesenchymal stem cell, which is administered through intravenous route. The drug candidate is being developed based on stem cell technology platform.

Baylx overview

Baylx is a biopharmaceutical company focused on the development of stem cell therapeutics for diseases in the areas with significant unmet medical needs. Baylx is headquartered in Irvine, California, the US.

For a complete picture of BXU-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.